What do the numbers say about Wockhardt Ltd. (WOCKPHARMA)? Here's a look at its financials, valuation, and ownership data.
Wockhardt Revenue Trend
Wockhardt Ltd. managed to grow its top line 6.7% in FY2025, with revenue hitting ₹3,074 Cr.
Revenue has contracted at 3.7% per year over 10 years, from ₹4,482 Cr to ₹3,074 Cr. The decline is gradual, but the direction is clear.
In terms of scale, Wockhardt Ltd.'s ₹3,074 Cr in annual revenue positions it as a mid-sized pharmaceuticals company.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹3,074 Cr | +6.7% |
| FY2024 | ₹2,881 Cr | +8.7% |
| FY2023 | ₹2,651 Cr | -17.9% |
| FY2022 | ₹3,230 Cr | +19.3% |
| FY2021 | ₹2,708 Cr | — |
View Wockhardt Ltd.'s full 10-year revenue trend with CAGR analysis →
Wockhardt Profitability
Per-share earnings moved to ₹-3.02 in FY2025 from ₹-32.05 in FY2024.
Is Wockhardt Undervalued
Running the numbers through the P/E Ratio model gives a fair value of ₹434 for Wockhardt Ltd..
Wockhardt Ltd. shares are currently trading at ₹2,073.90.
Craytheon also calculates intrinsic value using the EPS Growth model. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹434 | 79.1% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
See all valuation models for Wockhardt Ltd. with detailed assumptions →
Wockhardt Shareholding Pattern
At 49.1%, the promoter stake has been flat for the past 4 quarters.
Foreign investors held 7.1% of the company as of March 2026, down year-over-year from 7.3%.
Domestic institutional investors (DIIs) held 11.0% as of March 2026, down from 11.0% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 49.1% | 7.1% | 11.0% | 32.8% |
| Dec 2025 | 49.1% | 7.0% | 10.6% | 33.4% |
| Sep 2025 | 49.1% | 7.1% | 11.0% | 32.8% |
| Jun 2025 | 49.1% | 7.3% | 11.0% | 32.6% |
Track quarterly shareholding changes for Wockhardt Ltd. →
Wockhardt Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹81.35B, up 6.4% YoY from ₹76.49B.
Other Assets accounts for 40.7% of the total, ahead of Property, Plant & Equipment (23.2%) and Intangibles & Goodwill (12.5%).
Capital structure: 57.2% equity, 24.8% debt, 17.9% operating liabilities. Over the year, debt is down 14.2% and equity is up 27.2%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 5.34B |
| Receivables | 6.61B |
| Inventories | 7.25B |
| Property, Plant & Equipment | 18.86B |
| Intangibles & Goodwill | 10.18B |
| Other Assets | 33.11B |
| Category | Value |
|---|---|
| Equity | 46.57B |
| Short-term Debt | 7.15B |
| Long-term Debt | 13.06B |
| Trade Payables | 5.92B |
| Other Liabilities | 8.65B |
Wockhardt at a Glance
Here's the bottom line on Wockhardt Ltd. (WOCKPHARMA) based on the latest available financials.
Revenue of ₹3,074 Cr in FY2025, up 6.7% year-over-year.
Long-term revenue has been contracting at 3.7% annually over 10 years.
The company reported a net loss of ₹57.0 Cr in FY2025.
The P/E Ratio model implies 79.1% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Wockhardt Ltd..